Masimo and Philips have announced a renewed multi-year strategic collaboration to enhance patient monitoring technologies and develop new tools aimed at improving patient care. This partnership will focus on integrating Masimo’s SET pulse oximetry technology, which monitors oxygen saturation and pulse rate, into Philips’ multi-parameter patient monitors. The integration is expected to accelerate through 2026 and beyond, according to Masimo.
The status of Masimo’s relationship with Philips came under scrutiny during Masimo’s second-quarter earnings call in August. Analysts raised questions about the partnership, especially after competitor Medtronic renewed its own partnership with Philips in patient monitoring just a month earlier.
During the earnings call, Masimo’s CEO Katie Szyman, who joined the company from BD in February, reassured investors that the relationship with Philips remained strong. She highlighted that Masimo’s pulse oximetry technology is already available on Philips’ patient monitors and that technologies measuring continuous hemoglobin and brain function are also connected with other Philips devices.
As part of the renewed collaboration, Philips will expedite the adoption of these technologies in additional devices and market segments. The agreement also includes integrating Masimo’s Radius PPG wearable sensor technology with Philips monitors and next-generation wearable multi-parameter devices. Various Masimo sensors will be utilized with Philips bedside monitors and central stations.
BTIG analyst Marie Thibault noted that the expanded partnership aligns with the strategic initiatives outlined by Szyman earlier in the year. The partnership is seen as a positive development by analysts and industry experts.
Philips stated that the agreement with Masimo is in line with their broader strategy to promote vendor-neutral interoperability across healthcare systems. This collaboration signifies a commitment to advancing patient care through innovative technologies and partnerships.
